Cantargia AB (CHIX:CANTAS) Volatility: N/A% (As of Jun. 27, 2026)


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Volatility?

Cantargia AB CHIX:CANTAS 37 Volatility is N/A% as of Jun. 27, 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

Cantargia AB does not have enough data to calculate Volatility.

Cantargia AB  (CHIX:CANTAs) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Cantargia AB Volatility Related Terms

CHIX:CANTAS vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Cantargia AB's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantargia AB Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Volatility distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Volatility falls into.


CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB  (CHIX:CANTAs) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of N/A% mean?
Cantargia AB (CHIX:CANTAS) has a Volatility of N/A% as of Jun. 27, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cantargia AB and its competitors.
Is Cantargia AB's Volatility too high?
Cantargia AB's current Volatility is N/A%. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Volatility compare to VRTX and REGN?
Cantargia AB's Volatility of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Cantargia AB and its competitors. Cantargia AB's current Volatility is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Volatility of N/A%. The current Volatility is N/A%. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Volatility is N/A% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price